VBI Vaccines Overview

  • Year Founded
  • 1965

Year Founded

  • Status
  • Private

  • Employees
  • 138

Employees

  • Latest Deal Type
  • Bankr. Admin/​Reorg

VBI Vaccines General Information

Description

VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.

Contact Information

Formerly Known As
SciVac, Levon Resources, SciVac Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Private Debt Financed
Corporate Office
  • 160 Second Street
  • Floor 3
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 160 Second Street
  • Floor 3
  • Cambridge, MA 02142
  • United States
+1 (617)

VBI Vaccines Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VBI Vaccines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Bankruptcy: Admin/Reorg 02-Aug-2024 Completed Bankruptcy: Admin/Reorg
10. 2PO 15-May-2024 Completed Generating Revenue/Not Profitable
9. PIPE 11-Apr-2024 Completed Generating Revenue/Not Profitable
8. 2PO 07-Jul-2023 Completed Profitable
7. PIPE 10-Jul-2023 Completed Profitable
6. 2PO 17-Dec-2018 Completed Profitable
5. PIPE 06-Dec-2016 Completed Profitable
4. PIPE 21-Jun-2016 Completed Profitable
3. Reverse Merger 09-Jul-2015 Completed Profitable
2. Secondary Transaction - Private 05-Jun-2012 $700K Completed Profitable
To view VBI Vaccines’s complete valuation and funding history, request access »

VBI Vaccines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vac
Drug Discovery
Cambridge, MA
138 As of 2023

Basel, Switzerland
 

Baton Rouge, LA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VBI Vaccines Competitors (64)

One of VBI Vaccines’s 64 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
OncBioMune Corporate Backed or Acquired Baton Rouge, LA
IO Biotech Formerly VC-backed Copenhagen, Denmark
Quantum Genomics Corporation Paris, France
GSK Corporation Middlesex, United Kingdom
You’re viewing 5 of 64 competitors. Get the full list »

VBI Vaccines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VBI Vaccines Acquisitions (2)

VBI Vaccines’s most recent deal was a Merger/Acquisition with VBI Vaccines (Acquired in 2016) for . The deal was made on 06-May-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
VBI Vaccines (Acquired in 2016) 06-May-2016 Merger/Acquisition Drug Delivery
Levon Resources (acquired 2015) 09-Jul-2015 Merger/Acquisition Precious Metals and Minerals Mining
To view VBI Vaccines’s complete acquisitions history, request access »

VBI Vaccines ESG

Risk Overview

Risk Rating

Updated August, 30, 2022

28.65 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,842

Rank

Percentile

Pharmaceuticals

Industry

of 898

Rank

Percentile

Biotechnology

Subindustry

of 402

Rank

Percentile

To view VBI Vaccines’s complete esg history, request access »

VBI Vaccines FAQs

  • When was VBI Vaccines founded?

    VBI Vaccines was founded in 1965.

  • Where is VBI Vaccines headquartered?

    VBI Vaccines is headquartered in Cambridge, MA.

  • What is the size of VBI Vaccines?

    VBI Vaccines has 138 total employees.

  • What industry is VBI Vaccines in?

    VBI Vaccines’s primary industry is Drug Discovery.

  • Is VBI Vaccines a private or public company?

    VBI Vaccines is a Private company.

  • What is VBI Vaccines’s current revenue?

    The current revenue for VBI Vaccines is .

  • How much funding has VBI Vaccines raised over time?

    VBI Vaccines has raised $93.2M.

  • Who are VBI Vaccines’s competitors?

    Novartis, OncBioMune, IO Biotech, Quantum Genomics, and GSK are some of the 64 competitors of VBI Vaccines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »